IGF2BP1 and intrahepatic cholangiocarcinoma: C646, another small-molecule inhibitor, is identified to mitigate the mRNA and protein expression of IGF2BP1 in intrahepatic cholangiocarcinoma by inhibiting the levels of H3K27ac in its promoter 45.